Results 251 to 260 of about 31,066,857 (388)

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

Journal of Clinical Investigation, 2018
R. Das, Noffar Bar, Michelle N. Ferreira, Aaron M. Newman, Lin Zhang, Jithendra Kini Bailur, A. Bacchiocchi, H. Kluger, Wei Wei, R. Halaban, M. Sznol, M. Dhodapkar, K. Dhodapkar   +12 more
semanticscholar   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Defining three dimensional chromatin structures of pediatric and adolescent B cells using primary B cell and EBV-immortalized B cell reference genomes. [PDF]

BMC Med Genomics
Jiang K, Fu Y, Kelly JA, Gaffney PM, Holmes LC, Jarvis JN.   +5 more
europepmc   +1 more source

The Necessity for T Cell Help for Human Tonsil B Cell Responses to Pokeweed Mitogen: Induction of DNA Synthesis, Immunoglobulin, and Specific Antibody Production with a T Cell Helper Factor Produced with Pokeweed Mitogen [PDF]

, 1977
Richard A. Insel, Ezio Merler
openalex   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Galectin-9 treatment is cytotoxic for B cell lymphoma by disrupting autophagy. [PDF]

Front Pharmacol
Koll L, Lourens HJ, Marsman G, de Haan S, Niki T, Huls GA, Bremer E, Wiersma VR.   +7 more
europepmc   +1 more source

Studies on Japanese B encephalitis virus in cell cultures

, 1963
Jutarō Tawara, Kiyoshi Fujiwara, Takeo Utsumi, Masatoshi Maeda, Yoshimasa Mizuhara, Saizo Sakano   +5 more
openalex   +2 more sources

A New B Cell Differentiation Antigen (BDA) on Normal and Leukemic Human B Lymphocytes That Is Distinct from Known DR (Ia-Like) Antigens [PDF]

, 1978
Charles M. Balch, P. A. Dougherty, Larry B. Vogler, Edwin W. Ades, Soldano Ferrone   +4 more
openalex   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Biomarker-adapted treatment in high-risk large B-cell lymphoma. [PDF]

Hemasphere
Leppä S, Meriranta L, Arffman M, Jørgensen J, Karjalainen-Lindsberg ML, Beiske K, Pedersen M, Drott K, Pasanen A, Karihtala K, Mannisto S, Wold B, Brodtkorb M, Fagerli UM, Larsen TS, Munksgaard L, Sunela K, Fluge Ø, Jyrkkiö S, Brown P, Holte H.   +20 more
europepmc   +1 more source